Published: Mar, 2017
The global monoclonal antibody therapeutics market is dominated by well-established players, with little scope of fragmentation. However, Transparency Market Research states that the companies are struggling to retain their consumer bases and profits as patents are closing in on expiration dates. Owing to this reason, the competition in the global market is poised to intensify as it will open doors to new players and products in the near future. Currently, the leading players in the market are Pfizer Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Sanofi, and Merck & Co., Inc.
The research report by Transparency Market Research states that the global monoclonal antibody therapeutics market is expected to be worth US$245.8 bn by the end of 2024 from US$86.7 bn in 2015. The market is projected to exhibit a CAGR of 12.6% between the forecast years of 2016 and 2024.
North America Emerges as Leading Segment as Region Focuses toward Affordable Healthcare
Geographically, the global market is segmented into the Middle East and Africa, Latin America, Asia Pacific, Europe, and North America. The report indicates that North America held a dominant stance in the global market and is expected to continue its dominance in the coming years as well. The rise if this regional market will be due to the increasing focus on overall healthcare solutions being offered to the patients, affordable healthcare, and rising investments in research and development of improved therapeutics. By the end of forecast period, the global market is projected to account for a share of 37.9% in the global monoclonal antibody therapeutics market.
The application of monoclonal antibody therapeutics is seen for treating autoimmune diseases, cancer, infections, hematological diseases, ophthalmological diseases, and others. Of these, the demand for monoclonal antibody therapeutics to treat autoimmune diseases is expected to remain high during the forecast period. The segment is expected to rise at a CAGR of 13.5% in the overall market due to a high incidence of autoimmune diseases.
Improving Rate of Product Approvals Propels Market Growth
The global monoclonal antibody therapeutics market is being driven by improving rate of approval of products across Europe and the U.S. Both the regions are witnessing approval of about five to six monoclonal antibodies every year. The increasing usage of monoclonal antibodies in therapeutic areas has also given the market an additional boost. Today, monoclonal antibodies are being used in areas of orthopedics, inflammation, hematology, ophthalmology, inflammation, and for treating cardiovascular diseases. Several monoclonal antibodies are used for enhancing the immune system of cancer patients. Thus, the rising number of cancer cases in the coming years will also be a key growth driver for the overall market. A noted factor likely to propel the global market is the urgent need for cost-effective methods to treat asthma and rheumatology, which is being met through development of monoclonal antibodies.
Influx of Biosimilars Threatens Sales of Monoclonal Antibody Therapeutics
The global monoclonal antibody therapeutics market is being tugged in the opposite directions due to the influx of biosimilars in the market after the patent expiries of blockbuster drugs. The affordable pricing of these biosimilars is expected to eat into the market share of monoclonal antibody therapeutics. Furthermore, the high cost of monoclonal antibodies is also expected to dampen the market spirits in the forthcoming years. The strict approval procedures and the time-consuming process of manufacturing monoclonal antibody therapeutics raised the cost of these therapeutics over the years.
This review is based on Transparency Market Research’s report, titled “Monoclonal Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024.”
The monoclonal antibody therapeutics market has been segmented as follows:
Monoclonal Antibody Therapeutics Market, by Application
- Autoimmune diseases
- Hematological diseases
- Ophthalmological diseases
Monoclonal Antibody Therapeutics Market, by Source
Monoclonal Antibody Therapeutics Market, by End Users
- Private Clinics
- Research Institute
Monoclonal Antibody Therapeutics Market, by Geography
- North America
- Latin America
- Rest of Latin America
- Rest of Europe
- Asia Pacific
- New Zealand
- Rest of Asia Pacific
- Middle East and Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453